In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sensorion SAS, with a price target of €2.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors centered on the strength and progress of Sensorion’s GJB2 gene therapy program, SENS-601. He views the therapy’s AAV-based delivery, the robust preclinical evidence of functional hearing restoration in relevant GJB2 models, and the favorable safety profile seen in both mouse and non-human primate studies as validating the program’s potential.
Pantginis also highlights the approaching clinical trial application, expected in 1Q26, as a critical catalyst, given the first-mover positioning in a sizable, underserved genetic hearing loss market with no truly disease-modifying options beyond cochlear implants. The strong proof-of-concept data, including meaningful auditory threshold improvements and successful targeting of inner ear supporting cells, together with the ongoing natural history and CTA-enabling work, underpin his conviction that SENS-601 can be a major value driver for Sensorion SAS.
In another report released on January 30, TipRanks – Google also upgraded the stock to a Buy with a €0.42 price target.